摘要
糖尿病肾病(DN)是糖尿病最常见的并发症之一,是终末期肾病(ESRD)的主要原因。炎症反应在DN的病理过程中起着关键作用。NLRP3作为研究最深入的炎症小体,在DN中不容忽视。其异常激活加速DN进程。在这篇综述中,我们总结了我们对NLRP3炎症小体的结构组成和激活因子的认识。此外,我们还将讨论NLRP3炎症小体激活之间的关系,以及NLRP3炎症小体作为DN治疗靶点的潜力。
关键词: NLRP3炎症小体,糖尿病肾病(DN),炎症,NLRP3结构,终末期肾病(ESRD), DN进展。
Current Medicinal Chemistry
Title:Targeting the NLRP3 Inflammasome in Diabetic Nephropathy
Volume: 28 Issue: 42
关键词: NLRP3炎症小体,糖尿病肾病(DN),炎症,NLRP3结构,终末期肾病(ESRD), DN进展。
摘要: Diabetic nephropathy (DN) is one of the most common complications of diabetes and the main cause of end-stage renal disease (ESRD). The inflammatory response plays a key role in the pathological process of DN. As the most deeply studied inflammasome, NLRP3 should not be overlooked in DN. Its abnormal activation accelerates DN progression. In this review, we summarize our understanding of the structural composition and activation factors of the NLRP3 inflammasome. Moreover, the relationship between NLRP3 inflammasome activation, and the potential of the NLRP3 inflammasome as a therapeutic target for DN will also be discussed.
Export Options
About this article
Cite this article as:
Targeting the NLRP3 Inflammasome in Diabetic Nephropathy, Current Medicinal Chemistry 2021; 28 (42) . https://dx.doi.org/10.2174/0929867328666210705153109
DOI https://dx.doi.org/10.2174/0929867328666210705153109 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
Current Drug Targets Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets Molecular Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Hemodialysis Patients
Current Signal Transduction Therapy New Horizons in Diabetes Therapy: The Angiogenesis Paradox in Diabetes: Description of the Problem and Presentation of a Unifying Hypothesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Existing and Emerging Therapies for Acute Gout and Long-Term Urate Lowering
Current Rheumatology Reviews Local Renin-Angiotensin II Systems, Angiotensin-Converting Enzyme and its Homologue ACE2: Their Potential Role in the Pathogenesis of Chronic Obstructive Pulmonary Diseases, Pulmonary Hypertension and Acute Respiratory Distress Syndrome
Current Medicinal Chemistry Antiplatelet Treatment in Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Current Medicinal Chemistry Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety The Role of Angiotensin-Converting Enzyme in Immunity: Shedding Light on Experimental Findings
Endocrine, Metabolic & Immune Disorders - Drug Targets A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer’s Disease Pathogenicity: An Update
CNS & Neurological Disorders - Drug Targets The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design African Plants with Antidiabetic Potentials: Beyond Glycaemic Control to Central Nervous System Benefits
Current Diabetes Reviews A Review of Oxidative Stress Related Genes and New Antioxidant Therapy in Diabetic Nephropathy
Cardiovascular & Hematological Agents in Medicinal Chemistry Dicarbonyls Generation, Toxicities, Detoxifications and Potential Roles in Diabetes Complications
Current Protein & Peptide Science Human Leukocyte Antigens (HLA) Genes Association in Type 1 Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Mitigation of Radiation Injuries via Suppression of the Renin-Angiotensin System: Emphasis on Radiation Nephropathy
Current Drug Targets Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
Mini-Reviews in Medicinal Chemistry